What's happening at AdRegeneer?
AdRegeneer at Curious2024 – Future Insight e.V. Conference
11.07.2024
We are happy to participate in the Curious2024 – Future Insight e.V. Conference. It was an incredible event, and we enjoyed connecting and sharing our innovations with so many creative and inspiring minds.
AdRegeneer Named Finalist for GlobalCall24
14.06.2024
AdRegeneer is proud to announce our selection as a finalist for the GlobalCall24 in the Science Startups category by the Falling Walls Foundation. We look forward to the next steps and our participation in the Science Summit 2024 in Berlin. Congratulations to all the finalists!
Approval for Innosuisse Initial Coaching Programme!
12.06.2024
We are excited to announce that AdRegeneer has been approved for the prestigious Innosuisse Initial Coaching programme. We look forward to collobarote closely with Innosuisse.
Adregeneer Successfully Passed Scientific Advice Meeting with BfArM
09.04.2024
Adregeneer has reached a pivotal milestone in its clinical development journey by successfully passing the Scientific Advice Meeting with the Federal Institute for Drugs and Medical Devices (BfArM). With the green light from BfArM, Adregeneer is now primed to advance its Phase I and Phase II clinical trial plans towards the next stages of development.
Patent granted!
08.04.2024
We are thrilled to announce that one of our key patent applications has been granted in the United States! This milestone marks a significant step forward in our commitment to innovation and advancing regenerative medicine
W.A. de Vigier Award 2024
28.02.2024
Exciting news! Our startup has been chosen as one of the Top 50 finalists for the prestigious W.A. de Vigier Award 2024, recognizing our innovation and potential in the entrepreneurial landscape.
Neue Zürcher Zeitung!
19.11.2023
Our groundbreaking work has been shared by the prestigious Swiss newspaper Neue Zürcher Zeitung!
Fördern & Stiften Newsletter of JGU
19.11.23
Our co-founder Prof. Jacob's research on nervous system regeneration has shown promising results, including the identification of a protein that controls the activation of genes necessary for myelin rebuilding after damage. Professor Jacob's work, supported by the Mainzer Wissenschaftsstiftung and other generous supporters, has the potential to lead to significant advances in the treatment of MS and other neurological disorders.
Frankfurter Allgemeine Zeitung
19.10.2023
In the ever-evolving landscape of scientific discovery, we are thrilled to share that our work, featured in the prestigious Frankfurter Allgemeine Zeitung, has uncovered a breakthrough in the field of neurodegenerative diseases, particularly multiple sclerosis (MS) and nerve injuries.
XPRENEURS
28.07.2023
We are happy to announce that AdRegeneer has been accepted to join Batch #14 of XPRENEUR's three-month incubation program!
Healthcare Hackathon 2023
23.06.2023
AdRegeneer received the 3rd prize at the Healthcare Hackathon 2023. This was our 1st pitch in presence and 2nd pitch overall!
New Publication
09.07.2020
Discover our new publication in Nature Communications! In this article, we elucidate a major mechanism that controls myelination and remyelination after lesion and we identify a treatment that promotes remyelination in the peripheral and central nervous systems after traumatic or demyelinating lesions.
Podcast with Nele Handwerker: in English and in German
Prof. Jacob receives the IRP Schellenberg Research Prize
27.09.2018
Neurobiologist Prof. Dr. Claire Jacob has been awarded the IRP Schellenberg Research Prize. The International Foundation for Research in Paraplegia (IRP) awards this prize every two years to exceptional researchers in the field of paraplegia. This year, the award, which comes with a prize of 100,000 Swiss Francs, was split equally between Prof. Dr. Claire Jacob and neurobiologist Prof. Dr. Magdalena Götz from the Helmholtz Zentrum München.
